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Inmammalian cells, specific aminoacyl-transfer RNA (tRNA)
synthetases have cytokine functions that require interactions
with partners outside of the translation apparatus. Little is
known about these interactions and how they facilitate
expanded functions that link protein translation to other cellu-
lar pathways. For example, an alternative splice fragment of
tryptophanyl-tRNA synthetase (TrpRS) and a similar natural
proteolytic fragment are potent angiostatic factors that act
through the vascular endothelial-cadherin receptor andAkt sig-
naling pathway.Herewedemonstratemobilization ofTrpRS for
exocytosis from endothelial cells and the potential for plasmin
to activate the cytokine function of the extracellular synthetase.
Direct physical evidence showed that the annexin II-S100A10
complex, which regulates exocytosis, forms a ternary complex
with TrpRS. Functional studies demonstrate that both annexin
II and S100A10 regulate trafficking of TrpRS. Thus, complexes
of mammalian tRNA synthetases with seemingly disparate pro-
teins may in general be relevant to understanding how their
expanded functions are implemented.
Aminoacyl-tRNA2 synthetases (AARSs) arose early in evolu-
tion and established the genetic code by attaching specific
amino acids to their cognate tRNAs as the first step in protein
synthesis. Over their long evolution, AARSs acquired addi-
tional functions, includingRNA splicing, RNA trafficking, tran-
scriptional and translational regulation, apoptosis, and cell sig-
naling (1, 2). Thus, AARSs and aminoacyl-tRNA synthetase-
interacting multifunctional proteins (AIMP1, AIMP2, and
AIMP3) are active in signaling pathways outside of aminoacy-
lation and even of protein synthesis (3–11). The cell signaling
function has been demonstrated for naturally occurring frag-
ments of two closely related human AARSs, tyrosyl- (TyrRS)
and tryptophanyl-tRNA synthetase (TrpRS) (11–16). Here we
report on the cellular interactions of one of these, TrpRS, as a
required step in its gaining access to its extracellular receptor
for a signaling pathway in angiogenesis. The work also offers
potential insight into the many connections that are needed to
build up biological systems in higher organisms.
Of the different mechanisms by which proteins can switch
between functions, one way is by interacting with other fac-
tor(s) as part of a larger complex (17). Thus, AARSs and their
auxiliary factors form complexes with other proteins both
within and outside of the translational machinery that relates
these proteins to their noncanonical functions. For example,
glutamyl-prolyl-tRNA synthetase is a member of the GAIT
(interferon (IFN)--activated inhibitor of translation) complex
that binds to a structural element in the 3-untranslated region
of ceruloplasminmRNA and regulates its translation (10). Glu-
taminyl-tRNA synthetase has an anti-apoptotic role by inter-
acting with and inhibiting the apoptosis signal regulating
kinase-1 in a glutamine-dependent manner (7). Human lysyl-
tRNA synthetase is involved in the packaging of HIV virion via
the interaction of its N-terminalmotif with the C-terminal cap-
sid region of the HIV Gag protein (3). AIMP1, one of three
AARS auxiliary factors, interacts with -subunit of ATP syn-
thase and plays a role in proliferation of endothelial cells (18).
Recently, AIMP1 has been suggested to control the retention of
an endoplasmic reticulum-residentmember of theHSP90 fam-
ily, gp96, by enhancing gp96 dimerization and its interaction
with KDEL receptor-1 that, in turn, mediates retrieval of
KDEL-containing proteins from the Golgi to the endoplasmic
reticulum (19).
Mammalian TrpRSs contain an N-terminal appended
domain that is alternatively spliced to create mini-TrpRS (20,
21). The anti-angiogenic activity of mini-TrpRS and a mini-
TrpRS-like proteolytic variant, T2-TrpRS,was demonstrated in
several in vitro cell-based assays and, in addition, in vivo in the
three different animal models (chick chorioallantoic mem-
brane, mouse Matrigel model, and retinal tissues of the neona-
talmouse) (14, 16). T2-TrpRS interferes with cellular responses
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to angiogenic signals, such as proliferation and migration (16),
and cell signaling events that include activation of extracellular
signal-regulated kinase, protein kinase B (Akt), and nitric-oxide
synthase (22). In a shear stress model, T2-TrpRS inhibited
canonical responses to mechanical force, such as endothelial
cell alignment in direction of fluid flow (22). Subsequent work
established vascular endothelial (VE)-cadherin as a receptor for
T2-TrpRS that mediated its anti-angiogenic activity (23). This
potent activity can be elucidated through administration of
exogenous T2-TrpRS or delivery via gene therapy and has
found applications to angiogenesis-related disease of the eye
and to oncology (12, 14, 24).
Overexpression of TrpRS was observed during development
of the salivary gland in Drosophila (25), during delayed type
hypersensitivity reactions in guinea pigs (26) and in aged
human epidermis (27). The stimulus for this overexpression in
these instances was not established. However, earlier work
demonstrated that the antiproliferative cytokine IFN- up-reg-
ulated levels of TrpRS and mini-TrpRS mRNA (20, 28, 29).
IFN- regulates expression of hundreds of genes, some of
which are involved in host defense or inflammation (30),
whereas others are anti-angiogenic, such as IP-10 (interferon-
inducible protein-10) andMIG (monokine induced by -inter-
feron) (31, 32). Based on induction of TrpRS expression by
IFN-, and because fragments of TrpRS show angiostatic activ-
ity, we wondered whether IFN- played a role in up-regulating
TrpRS to poise it for mobilization and elaboration of its cyto-
kine activity. With this perspective, we started by investigating
the possibility of detecting secretion from cells that were stim-
ulatedwith IFN- and,more broadly, to identify the interacting
partners of TrpRS that were needed for its mobilization and
trafficking.
EXPERIMENTAL PROCEDURES
Cell Culture—Human umbilical vein endothelial cells
(HUVECs) and human lung microvascular endothelial cells
(HLMVECs) were obtained from Lonza (Basel, Switzerland)
and maintained in endothelial growth medium (EGM) (Lonza)
supplemented to 10% FBS (Invitrogen) and EGM-MV (Lonza),
respectively, and cultivated on gelatin-coated surfaces in an
atmosphere of 5%CO2 in air at 37 °C according to the supplier’s
instructions. C8161 cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (Invitrogen) supplemented with 10% FBS
and 1% solution of penicillin and streptomycin.
TrpRS Expression and Secretion—HUVECs were cultured to
60% confluence, washed twice with phosphate-buffered saline
(PBS) (Invitrogen) and further cultured in medium containing
2% FBS, with or without various concentrations of IFN-
(Roche Applied Science). At specific time points, the cells were
washed with PBS and collected in 40 mM Tris-HCl, pH 7.4, 150
mM NaCl, and 1 mM EDTA. The cells were centrifuged at 1500
rpm for 10 min at 4 °C and lysed in 25 mM HEPES, pH 8.0,
containing 5 mM EDTA and 0.1% CHAPS. The lysates were
separated using a 4–12% SDS-PAGE, transferred to polyvinyli-
dene difluoride membrane (Immobilon-P, Millipore, Billerica,
MA), and probed with antibodies against TrpRS, TyrRS, and
actin and sequential treatment with horseradish peroxidase-
conjugated secondary antibodies (Jackson Immunoresearch,
West Grove, PA). Western blots were developed using
enhanced chemiluminescence kit (GE Healthcare Bio-Sci-
ences, Uppsala, Sweden). To determine the effect of TGF-
(Roche Applied Science), IL-4 (R & D Systems, Minneapolis,
MN), and TNF- (Roche Applied Science) on TrpRS expres-
sion, HUVECs were transferred to 2% FBS containing endothe-
lial growth medium and stimulated with various concentra-
tions of these cytokines with or without IFN- (100 units/ml).
TrpRS expression was determined in whole cell lysates by
Western blot analysis.
To investigate whether TrpRS was secreted from HUVECs,
culture supernatants from IFN--treated cells were collected,
concentrated using Centricon-10 (Millipore), and analyzed by
Western blot analysis. Further, concentrated culture superna-
tants were precleared using protein G-Sepharose beads
(Pierce). Cleared supernatants were then incubated with pro-
tein G-Sepharose previously conjugated with anti-TrpRS anti-
body (rabbit) for 3 h at 4 °C with continuous mixing. The sam-
ples were washed thoroughly in lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mMNaCl, 1% Triton X-100, 0.1% SDS, 1 mM phen-
ylmethylsulfonyl fluoride, and protease inhibitor mixture tab-
lets (Roche Applied Science)), and the complexes were eluted
using SDS-PAGE sample buffer. The samples were resolved on
a 4–12% SDS-PAGE, andWestern blots were performed using
anti-TrpRS antibody (chicken) as primary and donkey anti-
chicken horseradish peroxidase as the secondary antibody.
Yeast and Bacterial Strains—Saccharomyces cerevisiae strain
AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4,
gal80, LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-
ADE2URA3::MEL1UAS-MEL1TATA-lacZ MEL 1) (Clontech,
Mountain View, CA)was used for all yeast two-hybrid analyses.
Escherichia coli strain DH5 was used for plasmid amplifica-
tion and other molecular biology protocols. E. coli strain
BL21(DE3) was used for protein expression.
Yeast Two-hybrid Analysis—Yeast two-hybrid analysis was
performed with the MATCHMAKER two-hybrid system
(Clontech) using a mouse 7-day embryo cDNA library (Clon-
tech), which was amplified in E. coli as per the manufacturer’s
protocols. Human Library transformations were made using
the Yeastmaker Yeast Transformation System 2 (Clontech).
The experimental setup aimed to reduce false positives by rely-
ing on three reporter genes: two auxotrophic markers (ADE2
and HIS3) and lacZ (which allows for measurement of -galac-
tosidase activity). TrpRS and T2-TrpRS were used as baits to
screen the library. Under high stringency conditions, 3–5 
107 yeast colonies were screened in four separate library trans-
formations. Positive clones were selected on selective plates
lacking leucine and tryptophan to allow for selection of the bait
and target plasmids that carried a Leu and Trp marker,
respectively, as well as histidine and adenine to enable selection
for interacting proteins. From these screens, 12 positive colo-
nies were isolated and further examined for -galactosidase
activity, which results from a protein-protein interaction that
activates the Lac promoter. Positive yeast colonies were grown
in liquidmediumovernight, andDNAwas extracted by treating
yeast cells with 400l of yeast cracking buffer (40mMTris-HCl,
pH 6.8, 8 M urea, 5% SDS, and 1 mM EDTA) and an equivalent
volume of glass beads. The cells were vigorously vortexed for 5
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min, and DNA was extracted in phenol-cholorform-isoamylal-
cohol (25:24:1). DNA was concentrated with ethanol, and the
insert region of target plasmid amplified by PCR using the
MATCHMAKER insert screening primers. PCR products were
sequenced, and the results were analyzed using BLAST (33).
Once identified, positive cloneswere reintroduced into the vec-
tor pACT2 (Clontech) by ligation into the SmaI/BamHI sites,
cotransformed into yeast with plasmids encoding TrpRS and
T2-TrpRS as bait. These experiments checked for the ability of
the transformed yeast to grow on high stringency plates and
also for induction of the lacZ reporter gene. In vitro binding to
T2-TrpRS was tested using MATCHMAKER coimmunopre-
cipitation kit (Clontech). [35S]Methionine-labeled protein
products were prepared for pull-down using the TNT coupled
reticulocyte lysate systems (Promega, Madison, WI).
Coimmunoprecipitation—Following stimulation of HUVECs
with IFN- for 24 h, the cells were washed with PBS and
extracted in lysis buffer (50mMTris-HCl, pH7.5, 150mMNaCl,
1%TritonX-100, 0.1%SDS, 0.5%Nonidet P-40, 1mMEGTA, 50
mM octyl glucoside, 10 mM sodium fluoride, 1 mM sodium van-
adate, and protease inhibitors) by passing several times through
22-gauge needle. The samples (106 cells) were precleared with
50 l of protein G-Sepharose at 4 °C. The supernatants were
then incubated with protein G-Sepharose previously conju-
gated with anti-TrpRS antibody for 3 h at 4 °C with continuous
mixing. The immunoprecipitates were washed thoroughly with
lysis buffer and eluted using SDS-PAGE sample buffer.Western
blot analysis was performed using anti-annexin II (Invitrogen)
and anti-S100A10 (BD Biosciences, San Jose, CA) antibodies
and horseradish peroxidase-conjugated goat anti-mouse sec-
ondary antibody. Similar immunoprecipitations were per-
formed using anti-annexin II and anti-S100A10 antibodies.
RNA Interference—RNA nucleotides were obtained from
Dharmacon Research (Lafayette, CO). A mix of four small
interfering RNA (siRNA) duplexes derived from different
regions of human annexin II (5-AGACCAAAGGUGUGGAU-
GAUU-3, 5-CUGUCAAAGCCUAUACUAAUU-3, 5-CGA-
CGAGGACUCUCUUCAUUUU-3, and 5-AUACUAACUU-
UGAUGCUGAUU-3) and human S100A10 (5-GAUAAAG-
GCUACUUAACAAUU-3, 5-GAAAAGGAGUUCCCUGG-
AUUU-3, 5-GAACACGCCAUGGAAACCAUU-3, and 5-
GGACCAGUGUAGAGAUGGCUU-3) was used for gene
silencing. For siRNA transfections, HLMVEC, HUVEC, and
C8161 cells were grown to 80% confluence and transfectedwith
2 g of each annealed siRNA duplex using a nucleofection kit
(Amaxa, Gaithersburg, MD). 24 h after transfection, the cells
were washedwith PBS and incubated inmedium containing 2%
FBSwith orwithout human IFN-. The cells were incubated for
another 20 h, following which cells and culture supernatants
were collected and analyzed for annexin II, S100A10, and
TrpRS by Western blot analyses.
TrpRS Purification and Plasmin Digestion—Human full-
length TrpRS was purified as described earlier (16). Briefly,
DNA encoding TrpRS (residues 1–471) was cloned in NdeI/
HindIII sites of pET-20b vector (Novagen, Madison, WI). The
expressed TrpRS (484 amino acids) has 13 extra residues at the
C terminus, including a six-histidine tag, from the vector
sequence. TrpRS was expressed in E. coli strain BL21(DE3)
(Novagen) by induction with 1 mM isopropyl -D-thiogalacto-
pyranoside for 4 h. The protein was purified from the superna-
tants of the lysed cells using nickel-nitrilotriacetic acid-agarose
column chromatography (Qiagen) according to the manufac-
turer’s instructions.
Plasmin from human plasma (Sigma) was used to digest
TrpRS. The digestions were performed at a TrpRS:Plasmin
ratio of 10:1 at 25 °C for 0.5, 1, 2, 4, 6, and 22 h in PBS. Protein
fragments so producedwere resolved on a 10%Bis-Tris gel. The
4-h sample was dialyzed against water and characterized using
MALDI-TOF mass spectrometry. The sample was also run on
SDS-PAGE and transferred to polyvinylidene difluoride mem-
brane, and the N termini of five prominent fragments were
characterized by Edman degradation.
RESULTS
TrpRS Expression in Endothelial Cells—IFN- up-regulates
expression of TrpRS and mini-TrpRS mRNA in several cell
types (20, 28). In HUVECs, the level of TrpRSmRNA increased
by 30-fold following IFN- treatment (29). Because previous
work only investigated the effect of IFN- on expression of
TrpRSmRNA, we treated HUVECmonolayers with increasing
concentrations of IFN- (50–250 units/ml) for 12 h and ana-
lyzed the levels of expressed protein. From Western blots of
whole cell lysates, IFN- was seen to stimulate expression of
full-lengthTrpRS and of lesser amounts ofmini- andT2-TrpRS
(Fig. 1A). Induction of TrpRS was time-dependent, with a con-
tinuous increase from 6 to 36 h, after which it reached a stable
plateau (Fig. 1B). In contrast, IFN- stimulation had no effect
on expression of actin or of TyrRS, a close homolog of TrpRS
(Fig. 1A). (Induction of TrpRSwas observed at concentration as
low as 0.3 unit/ml IFN-, and TrpRS expression increased by
5-fold with 3 units/ml (0.4 ng/ml) IFN-. Even greater expres-
sion was observed at higher concentrations of IFN-, beyond
the physiological range (supplemental Fig. S1).)
In addition, none of three other cytokines that were tested,
TNF-, TGF-, and IL-4, had any effect onTrpRS expression in
HUVECs (Fig. 1C). These experiments tested the three cyto-
kines individually and in combination with IFN-. Collectively,
these data demonstrate strong, specific, and dose-dependent
stimulation of TrpRS expression in HUVECs.
TrpRS Secretion from Endothelial Cells—As stated earlier,
full-length TrpRS is inactive in angiogenesis. Only the alterna-
tive splice fragmentmini-TrpRS and the closely similar proteo-
lytic fragment T2-TrpRS are potent angiostatic factors. The
strong up-regulation of expression by IFN- treatment was
most pronounced for full-length TrpRS. Thus, we surmised
that if the biological rationale for up-regulation was for signal-
ing in an angiogenesis pathway, thenTrpRS itself, in addition to
mini-TrpRS, would have to be secreted. Consistent with the
idea that TrpRS would be expected to be secreted, Favorova et
al. (34) showed that mammalian TrpRS is present in the exo-
crine part of the pancreas and in the pancreatic juice. After
secretion, TrpRS could be converted by cleavage (with an extra-
cellular protease such as plasmin) toT2-TrpRS. Indeed, in addi-
tion to native TrpRS, Favorova et al. (34) also detected, in the
pancreatic juice, fragments of TrpRS that correspond to the
molecular size of T2-TrpRS.
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To detect secretion of TrpRS from cultured cells, we investi-
gated culture supernatants of IFN- (200 units/ml)-stimulated
HUVECs at 6, 12, 18, 24, and 36 h. As compared with unstimu-
lated cultures, a sharp increase in secreted protein at 12 and
18 h was observed (Fig. 2A). This increase was detectable right
up to 36 h. Based on a quantitative analysis, the percentage of
secreted TrpRS at 24 h was 0.44 and 1.88%, without and with
IFN- induction, respectively. As shown by anti-actin (or anti-
GAPDH in supplemental Fig. S2) blots of culture supernatants,
no cell lysis was observed at any of these time points. (In sepa-
rate experiments we showed that, had cell lysis occurred, we
could have detected less that 0.2% of the total cellular GAPDH.
However, even at this level of sensitivity, no GAPDH was
detected in cell supernatants.) To confirm that the major
secreted protein was full-length TrpRS, anti-TrpRS antibody
was used to immunoprecipitate culture supernatants from
IFN- stimulated cultures. The immunoprecipitate was dis-
solved in SDS-PAGE loading dye and subjected to electro-
phoresis andWestern blot analysis using anti-TrpRS antibody.
A single band at 53 kDa, corresponding to the full-length
TrpRS, was observed (Fig. 2B).
TrpRS secretion was not inhibited by brefeldin A (supple-
mental Fig. S3), which is known to inhibit the classical secretion
pathway by causing disintegration of the Golgi apparatus and
redistribution of Golgi enzymes into the endoplasmic reticu-
lum. In the same experiment, brefeldin A inhibited secretion of
matrix metalloproteinase-2. A23187 stimulates calcium-
dependent exocytosis and enhances the release of thioredoxin,
IL-1, and galectin-3 (proteins known to be secreted by non-
classical pathway). TrpRS secretion was not affected by
A23187, thus suggesting that TrpRS may use a nonclassical
secretion pathway that is different from any of these proteins.
Identification of S100A10 as a TrpRS-interacting Protein—
The polypeptide sequence of native TrpRS does not contain
secretion signatures. This absence raised the possibility that
TrpRS associated with one or more proteins that are known
to be secreted and thereby was carried out of the cell. To
identify proteins that interact with TrpRS in vivo and possi-
bly aid its secretion, a mouse cDNA expression library,
derived from 7-day embryos, was screened using the Clon-
tech Matchmaker yeast two-hybrid system. Both a cDNA for
TrpRS and, separately, for T2-TrpRS were used as baits. Por-
tions of the following genes were identified in the positive
clones: glycosylphosphatidylinositol-specific phospholipase
D1, lymphocyte antigen 6 complex, TGF-, Niemen Pick type
C2 protein, and S100A10 (Table 1).
Subsequently, positive clones were individually retrans-
formed into yeast with plasmids encoding TrpRS and
T2-TrpRS as bait. As shown inTable 1, in the retrial of the yeast
two-hybrid system, upon cotransformation of various positive
clones with TrpRS and T2-TrpRS-containing plasmids, only
FIGURE 1. IFN- stimulates expression of TrpRS in HUVECs. A, concentration-
dependent up-regulation of TrpRS in HUVECs stimulated with IFN-. HUVEC
monolayers were stimulated with 50 –250 units/ml IFN- in 2% FBS contain-
ing medium for 12 h, and protein expression in whole cell lysates was deter-
mined by Western blotting with the indicated antibody. Bands correspond-
ing to positions of full-length (53 kDa), mini (48 kDa), and T2-TrpRS (43 kDa)
are indicated. The numbers on left side of the panel indicate the positions of
molecular mass markers in kDa. IFN- stimulation did not affect levels of
TyrRS, a homolog of TrpRS. Actin was used as a loading control. B, time-de-
pendent up-regulation of TrpRS in HUVECs stimulated with IFN-. Western
blot of HUVEC whole cell lysates stimulated with 200 units/ml IFN- for 6, 12,
24, 36, and 48 h. A continuous increase in TrpRS levels, upon IFN- stimula-
tion, was observed from 6 to 36 h, after which it reached a stable plateau.
C, TGF-, IL-4, and TNF- do not stimulate expression of TrpRS in HUVECs.
HUVEC cultures were stimulated with TGF- (0.1–2 nM) and IL-4 (10 –100
units/ml), with and without stimulation with 100 units/ml IFN-, and pro-
tein expression in whole cell lysates was determined by Western blot anal-
ysis with the indicated antibody. Tubulin was used as a loading control. In
a similar experiment, whole cell lysates from HUVECs stimulated with
TNF- (100 –1000 units/ml) and TNF- (500 units/ml), together with IFN-
(100 units/ml), were probed for TrpRS by Western blot analysis.
FIGURE 2. IFN- stimulates secretion of TrpRS in HUVECs. A, HUVEC mono-
layers were stimulated with 200 units/ml IFN-, and TrpRS levels were exam-
ined in whole cell lysates and supernatants at 6, 12, 18, 24, and 36 h after
stimulation. Secreted TrpRS was detected at 6 h, with an increase in secreted
protein at 12 and 18 h. The lack of actin in the culture supernatant (secreted
actin) indicates absence of cell lysis. B, supernatants from IFN- stimulated
cultures were further subjected to immunoprecipitation (IP) using anti-TrpRS
antibody. The immunoprecipitate was subjected to electrophoresis, and a
single band at 53 kDa, corresponding to the full-length TrpRS, was
observed in a Western blot using anti-TrpRS antibody (lane 2). Lane IgG was
loaded with proteins precipitated by rabbit IgG. The numbers on the right side
of the panel indicate the positions of molecular mass markers in kDa.
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cells harboring the cDNA encoding mouse TGF- or S100A10
grew in the absence of selective nutrients. Further, only the
S100A10 protein was able to stimulate production of -galac-
tosidase. Sequencing of the TGF--encoding clone revealed it
to be a portion of the 3-untranslated region of the gene. BLAST
searches using the predicted amino acid sequence of this clone
returned no significant homology to any known protein.
TrpRS Interacts with S100A10-Annexin II Complex—To fur-
ther confirm the interaction between S100A10 and TrpRS in
cultured cells, we performed coimmunoprecipitation experi-
ments usingHUVEC lysates. As observed byWestern blot anal-
ysis using anti-S100A10 antibodies, anti-TrpRS antibody coim-
munoprecipitated S100A10 (Fig. 3A). Aware that S100A10
forms a complexwith annexin II, we probed for and experimen-
tally confirmed the trimeric complex containing annexin II,
S100A10, and TrpRS. Thus, in our anti-TrpRS pull-down sam-
ples that demonstrated an interaction between S100A10 and
TrpRS, we probed for and easily detected annexin II.
To further confirm the complex formed from a S100A10,
annexin II, TrpRS interaction, we used anti-S100A10 and anti-
annexin II antibodies for pull-downs with HUVEC lysates. These
immunoprecipitates were then probed with anti-TrpRS antibod-
ies. A band corresponding to the size of TrpRS was clearly
detected in Western blots using anti-TrpRS antibodies (Fig.
3A). Based on quantitation of Western blots, 0.64 and 0.85% of
total TrpRS was associated with annexin II and S100A10,
respectively (supplemental Fig. S4).
Our results with the yeast two-hybrid system suggested that
the vertebrate-specific N-terminal extension (of 60 amino
acids) that regulates the cytokine function of TrpRS was not
needed for the interaction with S100A10. (As stated above, the
cytokine function is activated by removal of the vertebrate-spe-
cific N-terminal extension, through alternative splicing to give
mini-TrpRS (47 amino acids removed from the N terminus) or
by natural proteolysis to give the closely similar fragment
T2-TrpRS (93 amino acids removed from the N terminus.) To
further investigate the interaction of S100A10 with the angio-
static form of TrpRS, T2-TrpRS, we used pull-down of in vitro
translation products to study the ability of proteins to interact.
A natural fragment of human TyrRS, known as mini-TyrRS, is
the closest homolog of human T2-TrpRS. For both T2-TrpRS
andmini-TyrRS, the extraneous domains that are idiosyncratic
to TrpRS and TyrRS, respectively, have been stripped away,
thereby leaving the homologous core proteins. Thus, the poten-
tial interaction of S100A10 with in vitro translated mini-TyRS
was thought to be a good control.
T2-TrpRS (with c-Myc tag) and S100A10 (withHA tag) were
prepared by in vitro transcription/translation. The translation
products were immunoprecipitated with anti-HA antibodies,
and the precipitate was then dissolved and subsequently run on
an SDS-PAGE gel. A band corresponding to the size of
T2-TrpRS was readily detected, thus confirming the interac-
tion of S100A10with T2-TrpRS (Fig. 3B). In contrast, following
the same protocol with a c-Myc tag for the mini-TyrRS trans-
lation product, no interaction of S100A10withmini-TyrRSwas
seen (Fig. 3B). Other members of the S100 family, including
S100A8, A9, and A11, did not interact with T2-TrpRS in either
the yeast two-hybrid assay or pull-down experiments (data not
shown). Thus, the interaction of S100A10 with TrpRS appears
to be specific and to require a region of TrpRS that is common
to T2-TrpRS.
Functional Test for Annexin II and S100A10 as Interacting
Partners for TrpRS—The annexin II-S100A10 complex regu-
lates exocytosis in endothelial cells (35) and is crucial in routing
epithelial calcium channels, TRPV5 and TRPV6, to the plasma
membrane (36). To demonstrate a functional link that tested
for and expanded on the above stated genetic and physical evi-
dence for an interaction between annexin II, S100A10 and
TrpRS,we suppressed cellular levels of annexin II and S100A10,
using siRNAs. As depicted in Fig. 4A, transfection of primary
HLMVECs, with either a mix of four duplex annexin II or of
S100A10 siRNAs, resulted in a 90–95% decrease in levels of
annexin II and S100A10. In both cases, intracellular TrpRS lev-
els were not affected by the siRNA treatments. However,West-
ern blots of cell culture supernatants showed that upon IFN-
administration, knocking down S100A10 expression led to
higher levels of TrpRS in culture supernatants. Although not as
FIGURE 3. S100A10 interacts with TrpRS. A, coimmunoprecipitation of
annexin II and S100A10 with TrpRS. HUVEC lysates were subjected to immu-
noprecipitation using anti-TrpRS (I), anti-S100A10 (II), and anti-annexin II (III)
antibody coated on protein G beads. The precipitates were analyzed by West-
ern blots using indicated antibodies as probes. Lane IgG was loaded with
proteins precipitated by rabbit IgG-coated protein G beads. B, in vitro pull-
down assay. [35S]Methionine-labeled proteins were prepared by in vitro tran-
scription and translation, and immunoprecipitation was performed. The sam-
ples were run on SDS-PAGE and analyzed by autoradiography. Lane 1,
immunoprecipitation (IP) of Myc-T2-TrpRS with anti-c-Myc antibody; lane 2,
coimmunoprecipitation of Myc-T2-TrpRS and HA-S100A10 with anti-HA anti-
body; lane 3, immunoprecipitation of Myc-mini-TyrRS with anti-c-Myc anti-
body; lane 4, coimmunoprecipitation of Myc-mini-TyrRS and HA-S100A10
with anti-HA antibody. Myc-T2-TrpRS coimmunoprecipitated with HA-S100A10
(lane 2); Myc-mini-TyrRS, a similar size fragment of TyrRS, did not coimmunopre-
cipitate with HA-S100A10 (lane 4).
TABLE 1
List of clones identified by yeast two-hybrid analyses and the subsequent characterization of their interaction based on three assays
Clones Growth -Galactosidase Coimmunoprecipitation
Glycosylphosphatidylinositol-specific phospholipase D1   
Lymphocyte antigen 6 complex   
Niemen Pick type C2 protein   
TGF-   
S100A10   
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dramatic, depletion of annexin II in the same cells also caused
an elevation in levels of TrpRS. (As shown by anti-GAPDH
blots of culture supernatants (Fig. 4A and supplemental Fig.
S2), no cell lysis was observed during these experiments.) Thus,
the increased levels of TrpRS in the culture supernatants cor-
responded to its increased exocytosis from HLMVECs.
To investigate whether these observations could be extended
to other endothelial cell lines, we knocked down levels of
S100A10 and annexin II in HUVECs and in the C8161 mela-
noma cell line. When S100A10 expression was knocked down
(in the presence of IFN-), an increase in secretion of TrpRS
was observed in supernatants of HUVECs (Fig. 4B). In C8161
cells, although knocking down S100A10 levels slightly elevated
TrpRS secretion, a reduction in the expression of annexin II
caused a marked (in presence of IFN-) increase in secretion of
TrpRS (Fig. 4C). Thus, depending on the specific cell type,
knocking down expression of S100A10 (HUVECs) and of
annexin II (C8161 cells) significantly increased exocytosis of
TrpRS. (Quantitative analysis of the data showed that the
amount of secreted TrpRS is significantly increased in the pres-
ence of siRNAdirected against annexin II and S100A10, with or
without IFN- in HLMVECs. In HUVECs, siRNA against
S100A10 significantly enhancedTrpRS secretion, and inC8161
cells, siRNA against annexin II increased TrpRS secretion (sup-
plemental Table S2).)
These results further strengthen the connection between
S100A10 and annexin II with TrpRS, which was established by
direct genetic (two-hybrid selections) and physical (pull-down)
assays. Part of this connection seems to involve a role for
S100A10 alone or in complexwith annexin II in the cytoplasmic
retention of TrpRS, possibly as part of an endocytosis-exocyto-
sis cycling system. In this connection, the recent work of Reni-
gunta et al. (37) showed that S100A10 plays a similar role as a
cytoplasmic retention factor for TASK-1, an endoplasmic retic-
ulum potassium channel.
Processing of TrpRS into Its Angiostatic Forms by Plasmin—
The aforementioned results show that native, full-lengthTrpRS
is secreted and that annexin II and S100A10 affect cellular
export. Because angiogenesis is dependent upon the ability of
proteases to create locally new signaling molecules, major pro-
teases required for angiogenesis must cleave secreted full-
length TrpRS into angiostatic, truncated forms like T2-TrpRS.
Several proteases that are essential for angiogenesis release
from the extracellular matrix regulatory fragments like
endostatin, canstatin, and tumstatin by generating activated
fragments from inactive full-length proteins (38). Because the
angiostatic activity of TrpRS can only be seen when the enzyme
is split, one or more proteases are needed to process the
secreted native enzyme. With these considerations in mind,
plasmin is of particular interest
because of its extracellular location
on endothelial cells (39).
To pursuewhether plasmin could
produce the T2-/mini-TrpRS-like
fragments needed for angiostatic
activity, recombinant TrpRS (484
amino acids, including 13 extra res-
idues at the C terminus from the
vector) was cleaved with plasmin.
Five major fragments of TrpRS
were generated by plasmin diges-
tion and their identities deter-
mined by N-terminal sequencing
andMALDI-TOFmass spectrome-
try. Fig. 5A shows the pattern on a
SDS gel of fragments of TrpRS that
were obtained after incubation with
plasmin. The mass of the fragments
so generated was determined by
MALDI mass spectrometry (Fig.
5B). Mini-TrpRS and T2-TrpRS
begin at positions 48 and 94 in the
FIGURE 4. Knocking down annexin II and S100A10 facilitates TrpRS secre-
tion from cells. Expression of annexin II and S100A10 in HLMVEC (A), HUVEC
(B), and C8161 cells (C) was knocked down by either annexin II or S100A10
siRNAs. siRNA against green fluorescent protein and transfection medium
without siRNA (No siRNA) were used as controls. The transfected cells were
incubated for 20 h in culture medium supplemented with 200 units/ml
human IFN-, and cells and culture supernatants were collected. TrpRS,
annexin II, S100A10, and GAPDH were detected by Western blotting as
described under “Experimental Procedures.” The result is representative of
three separate experiments.
FIGURE 5. Cleavage of TrpRS by plasmin generates mini-TrpRS and T2-TrpRS-like fragments. A, SDS-PAGE
of TrpRS cleaved with plasmin. 5 g of TrpRS was incubated with plasmin at a TrpRS:Plasmin ratio of 10:1 at
25 °C, and samples were collected at 0.5, 1, 2, 4, 6, and 22 h and resolved on a 10% Bis-Tris gel (lanes 1– 6);
molecular mass markers are shown in lane 7. The numbers on right side of the panel indicate the positions of
molecular mass markers in kDa. B, MALDI-TOF mass spectrometry analysis of TrpRS incubated with plasmin for
4 h. The experimentally determined mass for each fragment is given on top of the corresponding peak. The
N-terminal residues (based on Edman degradation) of five prominent fragments (I–V) are given in parentheses
along with the predicted fragment size and expected mass based on amino acid sequence of the fragment.
Fragments II and IV and fragment V are similar to the angiostatic forms of TrpRS: mini-TrpRS and T2-TrpRS,
respectively.
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full-length TrpRS sequence, respectively. Fragments similar
to the angiostatic forms, mini-TrpRS (fragment II, cleavage
after Lys59 and Lys472; and fragment IV, cleavage after Lys59
andLys412) andT2-TrpRS (fragmentV, cleavage after Lys96 and
Lys349), were identified (Fig. 5B). Thus, once full-length TrpRS
is secreted, it can in principle be cleaved into angiostatic active
fragments by action of extracellular proteases such as plasmin.
Whether additional proteases can also process TrpRS in a sim-
ilar manner remains to be determined.
DISCUSSION
Based on our results, we infer that exocytosis of TrpRS
requires dissociation of TrpRS from the annexin II-S100A10
complex. (In separate experiments, upon IFN- stimulated
exocytosis of TrpRS, we did not observe an accompanying exo-
cytosis of annexin II or S100A10 (data not shown).) Once out-
side the cell, plasmin or another protease cleaves the native
enzyme into the angiostatic fragments. These fragments can
then inhibit the Akt signaling pathway through their known
interaction with VE-cadherin (Fig. 6).
In our experiments, on the order of 1% of TrpRS is tied up
with annexin II and with S100A10. At the same time, the
amount of secretion of TrpRS is also on the order of 1%. This
raises the question of how the small amount of TrpRS that is
associated with annexin II and S100A10 can prevent a greater
secretion of TrpRS. Possibly, the nonclassical secretory mech-
anism used by TrpRS has kinetic and thermodynamic parame-
ters that allow only a small fraction of the enzyme to be
secreted. It is also at least a formal possibility that a greater
percentage ofTrpRS is complexed to annexin II and S100A10 in
vivo than what we detected. The results of quantitation analysis
can depend on experimental conditions of the immunoprecipi-
tation procedure. (For example, dissociation of the complex
caused by lysis buffer components can lead to reduction in per-
centage of TrpRS bound to S100A10 and annexin II. Limited
binding of antibody to the antigen can also cause a reduction in
immunoprecipitation efficiency.) Additionally or alternatively,
TrpRS could also be complexed to other, unidentified cellular
proteins, including components of the translation apparatus, so
that only a small portion of the total TrpRS is present in a free
form that can be secreted from cells.
Protein export in mammalian cells usually occurs via the
classical secretory pathway that traverses the endoplasmic
reticulum and Golgi apparatus, where the secreted proteins
contain a signal sequence with all the information required to
target them for exocytosis. TrpRS appears not to follow this
pathway and to be more like the nonclassical examples, such as
basic fibroblast growth factor (FGF-2), FGF-1, interleukin-1,
HIV-tat, galectin-3, and thioredoxin, which are secreted in a
variety of nonclassical ways independent of the endoplasmic
reticulum-Golgi pathway (40). Of all the well studied nonclas-
sical export pathways, most is known about the secretion of
FGF-1. Two intracellular cleavage products of synaptotagmin,
p40-Syt1 and S100A13, associate with and are exported with
FGF-1 (40). The association of FGF-1 with p40-Syt1-S100A13
is the first step in the FGF-1 export pathway and is followed by
direct translocation of this protein complex across the plasma
membrane.
In several other examples, the heterotetrameric complex
(AIIt) of S100A10 and annexin II appears to play a role in non-
classical secretion. (Among other examples, down-regulation
of AIIt in HUVECs is associated with reduction in von Will-
ebrand factor secretion (41).) The data in Fig. 4 suggest that the
AIIt complex is involved in retaining TrpRS in the cytosol. Pre-
vious work demonstrated a similar role for S100A10 as a cyto-
plasmic retention factor for TASK-1 (37). In that work, RNA
interference directed against S100A10 caused enhanced traf-
ficking of TASK-1 to the cell surface membrane. Binding of
S100A10 to TASK-1 retarded the surface expression of the
channel, most likely by virtue of a di-lysine retention signal at
the C terminus of S100A10 that, in turn, is able to interact
with coat protein complex, which surrounds transport vesi-
cles in the early secretory pathway. Efficient forward traf-
ficking of TASK-1 has been suggested to require either dis-
sociation of S100A10 or masking of the retention signal on
S100A10 by another protein.
The connection of TrpRS to S100A10 and AIIt and possibly
the plasminogen-plasmin system invites speculation on one
of the many possible extratranslational roles of TrpRS. Plas-
minogen activation by cancer cells is usually initiated by the
release of urokinase-type plasminogen activator (uPA), which
is tightly bound by its cell surface receptor, uPAR. The colocal-
ization of plasminogenwith uPA-PAR complex stimulates con-
version of plasminogen to plasmin (42). Further, elevations in
uPA and its receptor have been demonstrated in a variety of
tumors including those of breast, bladder, colon, lung, ovary,
and prostate (43). The expressionof uPAbyneoplastic cells at the
invading front of cancerous tissue leads to a cascade of proteolytic
activities critical to local tumor growth and metastasis. Human
TrpRS secreted fromendothelial cells could be cleaved by plasmin
at the tumor-host interface, generating angiostatic fragments of
TrpRS that could then inhibit tumor growth.
More generally, the results presented here offer insight into
how mammalian tRNA synthetases are connected to cell sig-
FIGURE 6. Schematic mechanism of export and activation of TrpRS during
angiogenesis. Interaction of TrpRS with annexin II-S100A10 complex (AIIt)
regulates its retention in the cytosol. Dissociation of AIIt from TrpRS allows
export to the cell exterior. Proteases, such as plasmin, act on TrpRS to remove
the eucaryote-specific extension (shown in cyan), to generate T2-TrpRS.
T2-TrpRS then binds to cell surface receptor VE-cadherin and initiates the
angiostatic signaling pathway. tPA, tissue plasminogen activator; T2,
T2-TrpRS; Akt, protein kinase B.
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naling events outside of translation. By associating with key
factors in secretory and receptor signaling pathways, such as
the annexin II-S100A10 complex and VE-cadherin, a specific
tRNA synthetase is able to go from intracellular translation of
mRNA to cell signaling through a surface receptor. Under-
standing the networks built by protein-protein interactions
between seemingly disparate partners, such as those described
here, offers a specific framework for understanding how the
broad systems side of biology is assembled, starting with com-
ponents of the translation apparatus.
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